Urology News and Research

Latest Urology News and Research

Loyola University Medical Center to offer free prostate cancer screenings

More than 55 million American men are at risk for developing prostate cancer, according to the American Cancer Society. This year more than 27,000 men are expected to die of the disease, which is the second-leading cause of cancer death in men.

18 Aug 2010

Robotic prostatectomy has low complication rates: CINJ study

According to a new study by The Cancer Institute of New Jersey (CINJ), new evidence proves the safety of a robotic prostatectomy with the lowest complication rates in prostate cancer treatment. This comes as no surprise to Dr. David Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology at The Mount Sinai Medical Center in New York, who has performed over 3,000 successful robotic prostate surgeries in the fight against prostate cancer.

18 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

Beaver Medical Group expands range of ophthalmological services at Banning Specialty Care Center

Beaver Medical Group is expanding the range of ophthalmological services offered at its Banning Specialty Care Center. By relocating the SCC ophthalmology services within the facility and purchasing new technology, patients will have greater access and more convenience when they need eye care.

17 Aug 2010

High exposure to estrogens may cause gall bladder cancer: Research

A very aggressive disease with a poor prognosis, gallbladder cancer may be connected to higher exposure to estrogens, according to a group of researchers at the University of Houston (UH). Dr. Jan--ke Gustafsson, Robert A. Welch Professor in UH's biology and biochemistry department, described his team's findings in a paper titled "Estrogen-dependent gallbladder carcinogenesis in LXRβ-/- female mice" appearing in a recent issue of the journal Proceedings of the National Academy of Sciences, one of the world's most-cited multidisciplinary scientific serials.

17 Aug 2010

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.

16 Aug 2010

European Association of Urology to publish first case series on RALP

In European Urology, the official journal of the European Association of Urology, a new section will be published as of the September issue: Case Series of the month. This series is dedicated to publishing promising studies which have so far only preliminary results. The Case Series reports on no more than 10 patients and includes illustrative images. A Continuing Medical Education question with multiple choice answers is also included to enable readers to earn CME points.

13 Aug 2010

Severe inflammatory response to initial UTI causes bladder damage: Research

The immune system may open the door to recurrent urinary tract infections (UTIs) by overdoing its response to an initial infection, researchers at Washington University School of Medicine in St. Louis have found.Researchers showed in mice that severe inflammatory responses to an initial UTI cause bladder damage and allow infection to persist longer. After one to two weeks of infection, the bladder wall undergoes additional changes that leave mice more vulnerable to later infection. Suppressing the immune system during initial infection decreases these vulnerabilities, they report Aug. 12 in PLoS Pathogens.

13 Aug 2010

Antares Pharma second-quarter total revenue increases 78% to $3.1 million

Antares Pharma, Inc. today reported financial and operating results for the second quarter ended June 30, 2010.

13 Aug 2010

Warner Chilcott announces issue of $750M of senior notes due 2018 in private placement

Warner Chilcott plc today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC, plan to issue an aggregate principal amount of $750 million of senior notes due 2018 in a private placement.

12 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Tengion announces clinical, corporate and second-quarter financial updates

Tengion Inc. today provided a corporate and product development update and reported its financial results for the quarter ended June 30, 2010.

12 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

Study shows physicians reluctant to use finasteride for prostate cancer

Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

11 Aug 2010

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Penwest Pharmaceuticals Co. today announced that it has entered into a merger agreement under which its long-time partner in the development and commercialization of Opana ER, Endo Pharmaceuticals, has agreed to acquire all of the common stock of Penwest for $5.00 per share in cash. The total equity value of the transaction is approximately $168 million.

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Researchers for the first time have induced robust regeneration of nerve tissue connections in injured adult spinal cord sites that control voluntary movement. These findings provide hope that it may be possible to design therapies for paralysis and other impairments of motor function arising from spinal cord injury.

9 Aug 2010

Multiple tattoos increase risk of contracting hepatitis C: Study

Youth, prison inmates and individuals with multiple tattoos that cover large parts of their bodies are at higher risk of contracting hepatitis C and other blood-borne diseases, according to a University of British Columbia study.The researchers reviewed and analysed 124 studies from 30 countries, including Canada, Iran, Italy, Brazil and the United States, and found the incidence of hepatitis C after tattooing is directly linked with the number of tattoos an individual receives. The findings are published in the current issue of the International Journal of Infectious Diseases.

7 Aug 2010

Surgery offers high survival rate for prostate cancer patients: Study

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.

7 Aug 2010